Silo Pharma wins US patent allowance for SPC — 15 PTSD treatment claims
Silo Pharma received a USPTO notice of allowance for a U.S. patent covering SPC-15, an intranasal candidate for PTSD. Allowed claims cover compositions, methods to prevent or mitigate stress-induced behavioral responses. Decision extends IP protection for SPC-15, the company’s lead program. Japan previously issued a co